

Riccardo Soffiatti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6800011/publications.pdf>

Version: 2024-02-01

226
papers

23,308
citations

19608

61
h-index

9311

143
g-index

236
all docs

236
docs citations

236
times ranked

17999
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021, 23, 1231-1251.	0.6	4,534
2	Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 134-141.	0.8	1,703
3	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186.	12.5	826
4	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , The, 2017, 18, e315-e329.	5.1	816
5	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	5.1	776
6	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology</i> , The, 2015, 16, e270-e278.	5.1	711
7	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology</i> , The, 2014, 15, e395-e403.	5.1	647
8	EANO guidelines for the diagnosis and treatment of meningiomas. <i>Lancet Oncology</i> , The, 2016, 17, e383-e391.	5.1	627
9	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet</i> , The, 2009, 374, 1512-1520.	6.3	588
10	Brain metastases. <i>Nature Reviews Disease Primers</i> , 2019, 5, 5.	18.1	579
11	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1199-1208.	0.6	566
12	A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results. <i>Journal of Clinical Oncology</i> , 2013, 31, 65-72.	0.8	559
13	Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. <i>European Journal of Neurology</i> , 2011, 18, 19.	1.7	489
14	Guidelines on management of low-grade gliomas: report of an EFNS/EANO* Task Force. <i>European Journal of Neurology</i> , 2010, 17, 1124-1133.	1.7	428
15	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , 2017, 19, 162-174.	0.6	381
16	Management of brain metastases. <i>Journal of Neurology</i> , 2002, 249, 1357-1369.	1.8	343
17	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology</i> , The, 2015, 16, e322-e332.	5.1	340
18	STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. <i>Nature Medicine</i> , 2018, 24, 1024-1035.	15.2	285

#	ARTICLE	IF	CITATIONS
19	Epidemiology of glial and non-glial brain tumours in Europe. <i>European Journal of Cancer</i> , 2012, 48, 1532-1542.	1.3	248
20	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 110-119.	5.1	238
21	EANO guideline on the diagnosis and management of meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1821-1834.	0.6	230
22	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1043-1065.	0.6	209
23	Prognostic Factors in Well-Differentiated Cerebral Astrocytomas in the Adult. <i>Neurosurgery</i> , 1989, 24, 686-692.	0.6	207
24	Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. <i>Neuro-Oncology</i> , 2012, 14, iv55-iv64.	0.6	203
25	EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. <i>European Journal of Neurology</i> , 2006, 13, 674-681.	1.7	201
26	The Evolving Landscape of Brain Metastasis. <i>Trends in Cancer</i> , 2018, 4, 176-196.	3.8	194
27	EANO guidelines for the diagnosis and treatment of ependymal tumors. <i>Neuro-Oncology</i> , 2018, 20, 445-456.	0.6	173
28	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	0.8	160
29	Leptomeningeal metastases: a RANO proposal for response criteria. <i>Neuro-Oncology</i> , 2017, 19, now183.	0.6	157
30	PCV Chemotherapy for Recurrent Oligodendrogliomas and Oligoastrocytomas. <i>Neurosurgery</i> , 1998, 43, 1066-1073.	0.6	153
31	A prognostic gene expression signature in infratentorial ependymoma. <i>Acta Neuropathologica</i> , 2012, 123, 727-738.	3.9	148
32	Epilepsy and brain tumors. <i>Current Opinion in Oncology</i> , 2010, 22, 611-620.	1.1	145
33	Brain metastases: current management and new developments. <i>Current Opinion in Oncology</i> , 2008, 20, 676-684.	1.1	141
34	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. <i>Neuro-Oncology</i> , 2014, 16, 1176-1185.	0.6	141
35	PET imaging in patients with brain metastasis—report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019, 21, 585-595.	0.6	139
36	Histologic prognostic factors in ependymoma. <i>Child's Nervous System</i> , 1991, 7, 177-82.	0.6	138

#	ARTICLE	IF	CITATIONS
37	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017, 19, 625-635.	0.6	137
38	Mechanisms and Therapy for Cancer Metastasis to the Brain. <i>Frontiers in Oncology</i> , 2018, 8, 161.	1.3	123
39	Ependymomas in Adults. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 240-247.	2.0	122
40	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e407-e416.	5.1	119
41	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e396-e406.	5.1	116
42	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019, 21, 26-36.	0.6	114
43	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2019, 21, 571-584.	0.6	114
44	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 1994-1999.	0.6	105
45	Management of brain metastases according to molecular subtypes. <i>Nature Reviews Neurology</i> , 2020, 16, 557-574.	4.9	104
46	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. <i>Neuro-Oncology</i> , 2015, 17, 440-447.	0.6	102
47	The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in "Western" patients with intravascular large B-cell lymphoma. <i>British Journal of Haematology</i> , 2008, 143, 253-257.	1.2	96
48	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020, 22, 17-30.	0.6	94
49	Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. <i>Journal of Neuro-Oncology</i> , 2012, 106, 353-366.	1.4	93
50	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e20-e32.	5.1	87
51	Ependymoma: Internal Correlations among Pathological Signs: The Anaplastic Variant. <i>Neurosurgery</i> , 1991, 29, 206-210.	0.6	82
52	Natural history and management of brainstem gliomas in adults. <i>Journal of Neurology</i> , 2008, 255, 171-177.	1.8	82
53	Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection. <i>JAMA Oncology</i> , 2019, 5, 243.	3.4	81
54	Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. <i>Neuro-Oncology</i> , 2013, 15, 1739-1749.	0.6	76

#	ARTICLE	IF	CITATIONS
55	Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1155-1164.	3.3	76
56	Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring. <i>BioMed Research International</i> , 2018, 2018, 1-16.	0.9	76
57	Primitive cerebral melanoma: case report and review of the literature. <i>World Neurosurgery</i> , 2001, 55, 163-168.	1.3	75
58	Ependymomas of the adult: molecular biology and treatment. <i>Current Opinion in Neurology</i> , 2008, 21, 754-761.	1.8	75
59	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021, 23, 881-893.	0.6	75
60	Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.4	71
61	Breast cancer brain metastasis: molecular mechanisms and directions for treatment. <i>Neuro-Oncology</i> , 2018, 20, 1439-1449.	0.6	66
62	Brain metastases from unknown primary tumour. <i>Journal of Neurology</i> , 2001, 248, 394-398.	1.8	65
63	Targeted therapy in brain metastasis. <i>Current Opinion in Oncology</i> , 2012, 24, 679-686.	1.1	64
64	NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. <i>International Journal of Molecular Sciences</i> , 2020, 21, 753.	1.8	62
65	Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. <i>Neuro-Oncology</i> , 2021, 23, 812-826.	0.6	60
66	Bloodâ€ Brain Barrier in Brain Tumors: Biology and Clinical Relevance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12654.	1.8	59
67	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. <i>Neuro-Oncology</i> , 2016, 18, 744-751.	0.6	58
68	Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System. <i>Brain Pathology</i> , 2013, 23, 584-594.	2.1	53
69	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016, 18, 401-407.	0.6	53
70	Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. <i>Journal of Neuro-Oncology</i> , 2017, 133, 419-427.	1.4	52
71	Prognostic value of histologic factors in adult cerebral astrocytoma. <i>Cancer</i> , 1988, 61, 1386-1393.	2.0	49
72	Endocrine dysfunction in patients operated on for non-pituitary intracranial tumors. <i>European Journal of Endocrinology</i> , 2006, 155, 559-566.	1.9	48

#	ARTICLE	IF	CITATIONS
73	Neurologic complications of chemotherapy and other newer and experimental approaches. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 121, 1199-1218.	1.0	47
74	MGMT promoter methylation in plasma of glioma patients receiving temozolomide. Journal of Neuro-Oncology, 2014, 117, 347-357.	1.4	43
75	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e33-e42.	5.1	42
76	MRI diagnosis of intramedullary metastases from extra-CNS tumors. European Radiology, 1997, 7, 732-736.	2.3	39
77	Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy. Cancer, 2004, 100, 807-813.	2.0	39
78	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro-Oncology, 2022, 24, 1613-1646.	0.6	39
79	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neuro-Oncology, 2020, 22, 1568-1579.	0.6	38
80	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-Oncology, 2022, 24, 855-871.	0.6	38
81	Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. European Journal of Cancer, 2012, 48, 3439-3447.	1.3	37
82	Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. Neuro-Oncology, 2016, 18, 261-268.	0.6	36
83	Histological observations on the regrowth of malignant gliomas after radiotherapy and chemotherapy. Acta Neuropathologica, 1982, 58, 291-299.	3.9	35
84	Prognostic Factors in Adult Medulloblastoma. A Clinico-Pathologic Study. Tumori, 1995, 81, 338-346.	0.6	35
85	Radiotherapy and chemotherapy of brain metastases. Journal of Neuro-Oncology, 2005, 75, 31-42.	1.4	35
86	Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. Journal of Neuro-Oncology, 2018, 136, 105-114.	1.4	34
87	Use of Antidepressants and Risk of Incident Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology, 2019, 53, 142-151.	1.1	34
88	What is New in the Management of Epilepsy in Gliomas?. Current Treatment Options in Neurology, 2015, 17, 351.	0.7	33
89	Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. Cancer Letters, 2020, 480, 24-28.	3.2	33
90	Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001. Annals of Oncology, 2017, 28, 2588-2594.	0.6	31

#	ARTICLE	IF	CITATIONS
91	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. <i>Nature Medicine</i> , 2022, 28, 752-765.	15.2	30
92	Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches. <i>Cancers</i> , 2021, 13, 2888.	1.7	26
93	Radio- and chemotherapy of malignant gliomas. Pathological changes in the normal nervous tissue. <i>Acta Neurochirurgica</i> , 1981, 58, 37-58.	0.9	25
94	Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. <i>European Journal of Cancer</i> , 2017, 82, 193-202.	1.3	25
95	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2019, 129, 63-71.	0.9	25
96	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	0.6	25
97	Ependymoma: Evaluation and Management Updates. <i>Current Oncology Reports</i> , 2022, 24, 985-993.	1.8	25
98	Delayed adverse effects after irradiation of gliomas: clinicopathological analysis. <i>Journal of Neuro-Oncology</i> , 1985, 3, 187-192.	1.4	24
99	Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 45-56.	1.8	24
100	Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. <i>Oncotarget</i> , 2016, 7, 21190-21198.	0.8	24
101	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop. <i>Neuro-Oncology</i> , 2014, 16, 173-178.	0.6	23
102	Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps. <i>European Radiology</i> , 2016, 26, 1263-1273.	2.3	23
103	Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association) Tj ETQq1 1 0.784314 rgBT /Over <i>Neuro-Oncology</i> , 2019, 145, 115-123.	1.4	23
104	A comprehensive characterization of mitochondrial DNA mutations in glioblastoma multiforme. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 63, 46-54.	1.2	22
105	Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. <i>BMC Cancer</i> , 2015, 15, 486.	1.1	21
106	Proliferating Cell Nuclear Antigen (PCNA) in Low-Grade Astrocytomas: Its Prognostic Significance. <i>Tumori</i> , 1994, 80, 295-300.	0.6	20
107	Brain metastases. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012, 105, 747-755.	1.0	20
108	Management of Brain and Leptomeningeal Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8534.	1.8	19

#	ARTICLE	IF	CITATIONS
109	New developments in the treatment of malignant gliomas. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1313-1326.	1.4	18
110	Overview on current treatment standards in high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 225-238.	0.4	18
111	Primary Lymphomas of the Brain: A Clinico-Pathologic Review of 37 Cases. <i>Tumori</i> , 1987, 73, 585-592.	0.6	17
112	Caveolin 1 Expression Independently Predicts Shorter Survival in Oligodendrogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 425-431.	0.9	17
113	Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641875961.	1.5	17
114	New chemotherapy options for the treatment of malignant gliomas. <i>Anti-Cancer Drugs</i> , 2007, 18, 621-632.	0.7	16
115	Anti-Angiogenic Approaches to Malignant Gliomas. <i>Current Cancer Drug Targets</i> , 2012, 12, 279-288.	0.8	16
116	Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents. <i>Cancers</i> , 2020, 12, 3350.	1.7	16
117	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. <i>European Journal of Cancer</i> , 2021, 156, 93-108.	1.3	16
118	Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. <i>Oncotarget</i> , 2017, 8, 67696-67708.	0.8	16
119	Chemotherapy of anaplastic oligodendroglial tumours. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 295-306.	0.9	15
120	Controversies in management of low-grade gliomas in light of new data from clinical trials. <i>Neuro-Oncology</i> , 2017, 19, 143-144.	0.6	15
121	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. <i>Journal of Neurosurgical Sciences</i> , 2020, 64, 313-334.	0.3	15
122	What have we learned from trials on antiangiogenic agents in glioblastoma?. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 1-3.	1.4	14
123	Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 655-670.	1.8	14
124	A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: The NeuroCOVID-19 Task Force of the European Academy of Neurology. <i>European Journal of Neurology</i> , 2021, 28, 3849-3855.	1.7	14
125	Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 45-56.	1.8	14
126	Comparative genomic analysis of primary tumors and paired brain metastases in lung cancer patients by whole exome sequencing: a pilot study. <i>Oncotarget</i> , 2020, 11, 4648-4654.	0.8	14

#	ARTICLE	IF	CITATIONS
127	Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group. <i>Neuro-Oncology</i> , 2022, 24, 1815-1826.	0.6	14
128	Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. <i>Neuro-Oncology</i> , 2017, 19, now244.	0.6	13
129	Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective. <i>European Journal of Neurology</i> , 2021, 28, 3226-3229.	1.7	13
130	A call from the European Academy of Neurology on COVID-19. <i>Lancet Neurology</i> , The, 2020, 19, 482.	4.9	13
131	Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2007-2007.	0.8	13
132	IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups. <i>Neuro-Oncology</i> , 2022, 24, 809-820.	0.6	13
133	COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper. <i>European Journal of Neurology</i> , 2022, 29, 2163-2172.	1.7	13
134	Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview. <i>Cancers</i> , 2021, 13, 2114.	1.7	12
135	Evaluation of the 2020 European Academy of Neurology virtual congress: transition from a face-to-face to a virtual meeting. <i>European Journal of Neurology</i> , 2021, 28, 2523-2532.	1.7	12
136	Systemic Therapy for Lung Cancer Brain Metastases. <i>Current Treatment Options in Oncology</i> , 2021, 22, 110.	1.3	12
137	Supratotal Resection of Glioblastoma: Is Less More?. <i>Surgical Technology International</i> , 2019, 35, 432-440.	0.1	12
138	A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. <i>EMBO Molecular Medicine</i> , 2022, 14, e14552.	3.3	12
139	Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program. <i>Cancers</i> , 2022, 14, 1192.	1.7	12
140	Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects. <i>Biomedicines</i> , 2022, 10, 644.	1.4	12
141	Skin metastases of glioblastoma in the absence of intracranial progression are associated with a shift towards a mesenchymal immunophenotype: report of two cases. <i>Acta Neuropathologica</i> , 2009, 118, 313-316.	3.9	11
142	Treatment of brain metastasis: current status and future directions. <i>Current Opinion in Oncology</i> , 2016, 28, 502-510.	1.1	11
143	Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. <i>PLoS ONE</i> , 2018, 13, e0203570.	1.1	11
144	Antiangiogenic therapy of brain tumors: the role of bevacizumab. <i>Neurological Sciences</i> , 2014, 35, 507-514.	0.9	10

#	ARTICLE	IF	CITATIONS
145	Pharmacologic Therapies for Malignant Glioma: A Guide for Clinicians. <i>CNS Drugs</i> , 2014, 28, 1127-1137.	2.7	10
146	Rare glial tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 399-415.	1.0	10
147	Extent of surgery in low-grade gliomas: an old question in a new context. <i>Neuro-Oncology</i> , 2018, 20, 6-7.	0.6	10
148	Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors. <i>World Neurosurgery</i> , 2019, 126, e270-e280.	0.7	10
149	Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 248-256.	0.9	10
150	Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas. <i>Neuroradiology</i> , 1992, 34, 73-76.	1.1	9
151	The legend of cytomegalovirus and glioblastoma lives on. <i>Neuro-Oncology</i> , 2014, 16, 166-166.	0.6	9
152	Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature. <i>Frontiers in Neurology</i> , 2021, 12, 669493.	1.1	9
153	Clinical Significance of Molecular Alterations and Systemic Therapy for Meningiomas: Where Do We Stand?. <i>Cancers</i> , 2022, 14, 2256.	1.7	9
154	The Role of Intra-cerebrospinal Fluid Treatment and Prophylaxis in Patients With Solid Tumors. <i>Seminars in Oncology</i> , 2009, 36, S55-S68.	0.8	8
155	Does valproic acid affect tumor growth and improve survival in glioblastomas?. <i>CNS Oncology</i> , 2016, 5, 51-53.	1.2	8
156	Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early <i>Versus</i> Delayed Administration. <i>Anticancer Research</i> , 2018, 38, 5877-5881.	0.5	8
157	Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. <i>Neuro-Oncology</i> , 2019, 21, 1610-1611.	0.6	8
158	Current clinical management of elderly patients with glioma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1037-1048.	1.1	8
159	Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?. <i>Current Opinion in Neurology</i> , 2020, 33, 707-715.	1.8	8
160	Vascular response to irradiation in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 1990, 8, 73-84.	1.4	7
161	Bevacizumab Treatment for Vestibular Schwannoma in a Patient with Neurofibromatosis Type 2: Hearing Improvement and Tumor Shrinkage. <i>Tumori</i> , 2015, 101, e167-e170.	0.6	7
162	Molecularly based management of gliomas in clinical practice. <i>Neurological Sciences</i> , 2015, 36, 1551-1557.	0.9	7

#	ARTICLE	IF	CITATIONS
163	Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis?. <i>Neuro-Oncology</i> , 2016, 18, 12-15.	0.6	7
164	What Have We Learned from Recent Clinical Studies in Low-Grade Gliomas?. <i>Current Treatment Options in Neurology</i> , 2018, 20, 33.	0.7	7
165	Intracranial Meningiomas: A Systematic Analysis of Prognostic Factors for Recurrence in a Large Single Institution Surgical Series. <i>World Neurosurgery</i> , 2019, 123, e273-e279.	0.7	7
166	Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. <i>Journal of Neuro-Oncology</i> , 2010, 97, 439-444.	1.4	6
167	Imaging and clinical end points in brain metastases trials. <i>CNS Oncology</i> , 2017, 6, 243-246.	1.2	6
168	Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors. <i>Neurology</i> , 2019, 93, 217-219.	1.5	6
169	Effects of radiotherapy on the astrocytomatous areas of malignant gliomas. <i>Journal of Neuro-Oncology</i> , 1984, 2, 167-75.	1.4	5
170	The position of the neurologist in neuro-oncology1. <i>European Journal of Neurology</i> , 2002, 9, 201-205.	1.7	5
171	Still a long way to go to achieve multidisciplinary for the benefit of patients: commentary on the ESMO position paper (<i>Annals of Oncology</i> 25(1): 9â€“15, 2014). <i>Annals of Oncology</i> , 2014, 25, 1863-1865.	0.6	5
172	Evidence-based management of adult patients with diffuse glioma â€“ Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e430-e431.	5.1	5
173	Neuro-oncology perspective of treatment options in metastatic breast cancer. <i>Future Oncology</i> , 2018, 14, 1765-1774.	1.1	5
174	Cumulative intracranial tumour volume prognostic assessment: a new predicting score index for patients with brain metastases treated by stereotactic radiosurgery. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 499-508.	1.7	5
175	Leptomeningeal metastases from non-small cell lung cancer: state of the art and recent advances. <i>Journal of Cancer Metastasis and Treatment</i> , 0, 2020, .	0.5	5
176	Successful use of bevacizumab in an adult primary diffuse leptomeningeal glioneuronal tumor. <i>Journal of Neurosurgical Sciences</i> , 2018, 62, 229-232.	0.3	5
177	Strategies to prevent brain metastasis. <i>Current Opinion in Oncology</i> , 2019, 31, 493-500.	1.1	4
178	Targeted Therapies in Rare Brain Tumours. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7949.	1.8	4
179	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2047-2047.	0.8	4
180	On the Nature of the So-Called Monstrocellular Sarcoma of the Brain. <i>Neurosurgery</i> , 1980, 6, 391-397.	0.6	3

#	ARTICLE	IF	CITATIONS
181	Neuro-oncology: new insights and advances in treatment. <i>Lancet Neurology</i> , The, 2008, 7, 14-16.	4.9	3
182	Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response. <i>Journal of Neuro-Oncology</i> , 2016, 127, 201-203.	1.4	3
183	Natural History and Spontaneous Prognostic Factors. , 2013, , 265-275.		3
184	Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendroglial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO).. <i>Journal of Clinical Oncology</i> , 2012, 30, 2037-2037.	0.8	3
185	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2056-2056.	0.8	3
186	Ependymomas, neuronal and mixed neuronal-glial tumors, dysembroblastic neuroepithelial tumors, pleomorphic xanthoastrocytomas, and pilocytic astrocytomas. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 105, 551-567.	1.0	2
187	Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. <i>Progress in Neurological Surgery</i> , 2018, 31, 168-179.	1.3	2
188	Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1272-1275.	0.6	2
189	Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2045-2045.	0.8	2
190	Carcinomatosi meningeae cranicae et spinale: Studio con RM. <i>The Neuroradiology Journal</i> , 1997, 10, 585-595.	0.1	1
191	Ask the Experts: Ependymoma: current treatment options and a look to the future. <i>CNS Oncology</i> , 2013, 2, 223-225.	1.2	1
192	Solitary Brain Metastasis As First Manifestation of Small-Cell Parotid Gland Carcinoma With High Sensitivity to Temozolomide Therapy on Basis of Tumor O ⁶ -Methylguanine-DNA-Methyltransferase Expression. <i>Journal of Clinical Oncology</i> , 2013, 31, e394-e397.	0.8	1
193	Reply to M.C. Chamberlain and C. Gemici. <i>Journal of Clinical Oncology</i> , 2013, 31, 2636-2637.	0.8	1
194	Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study. <i>Neurological Sciences</i> , 2016, 37, 2019-2023.	0.9	1
195	Choosing appropriate chemotherapy for diffusely infiltrating WHO grade II gliomas in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 613-615.	0.9	1
196	Richter's Syndrome of the Central Nervous System. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-4.	0.3	1
197	Oligodendroglial Tumors. , 1997, , 214-227.		1
198	Spinal melanocytoma with leptomeningeal spread and long survival following surgery and chemotherapy. <i>Journal of Neurosurgical Sciences</i> , 2018, 62, 375-378.	0.3	1

#	ARTICLE	IF	CITATIONS
199	A Pathologic Study of Malignant Gliomas Operated after Radio- and Chemotherapy. <i>Tumori</i> , 1981, 67, 13-17.	0.6	0
200	Automatic segmentation and therapy follow-up of cerebral glioma in diffusion-tensor images. , 2010, ,		0
201	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 20-26.	2.2	0
202	PRE-OPERATIVE CHEMOTHERAPY AS A NEW STRATEGY OF TREATMENT FOR LOW GRADE GLIOMAS IN ELOQUENT AREAS. <i>Neuro-Oncology</i> , 2014, 16, iii45-iii45.	0.6	0
203	Does intensification of chemotherapy in anaplastic oligodendrogliomas still have a role?. <i>Neuro-Oncology</i> , 2017, 19, 1292-1293.	0.6	0
204	Brain Metastasis as Complication of Systemic Cancers. , 2018, , 57-79.		0
205	Editorial: Hot Topics in Neuro-Oncology. <i>Current Opinion in Neurology</i> , 2018, 31, 718-719.	1.8	0
206	Tumors of the Central Nervous System: Therapeutic Approaches. , 2019, , 69-83.		0
207	Does an optimal management of brain metastases from oncogenic-driver nonâ€“small cell lung cancer exist?. <i>Neuro-Oncology</i> , 2020, 22, 171-172.	0.6	0
208	Editorial: Neuro-oncology is moving ahead: new perspectives and critical issues. <i>Current Opinion in Neurology</i> , 2020, 33, 699-700.	1.8	0
209	Long-term survival of a sacro-coccygeal myxopapillary ependymoma with extra-neural metastases: case report and review of the literature. <i>Neurological Sciences</i> , 2020, 41, 1955-1957.	0.9	0
210	Evidence-based approaches to chemotherapy for gliomas. , 2021, , 38-52.		0
211	Brain metastases. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118015.	0.3	0
212	Assesment of clinical prognostic factors in elderly glioblastoma patients: An unmet need. <i>Journal of the Neurological Sciences</i> , 2021, 429, 117756.	0.3	0
213	Monitoring of cognitive functions and quality of life, in glioblastomas treated with regorafenib. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118445.	0.3	0
214	Ependymomas. , 2011, , 249-262.		0
215	Bevacizumab and temozolomide in secondary gliomatosis from gemistocytic astrocytoma: a case report. <i>Clinical Management Issues</i> , 2012, 6, 43-50.	0.3	0
216	Leptomeningeal metastases: A rano proposal for response criteria.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13019-e13019.	0.8	0

#	ARTICLE	IF	CITATIONS
217	MGMT gene promoter methylation in plasma of glioma patients receiving temozolomide.. Journal of Clinical Oncology, 2014, 32, 2016-2016.	0.8	0
218	GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.. Journal of Clinical Oncology, 2015, 33, 2054-2054.	0.8	0
219	Is there a Role for Bevacizumab in Non-Glial Tumors?. Current Drug Targets, 2015, 16, 684-688.	1.0	0
220	Does the duration of adjuvant temozolomide impact survival in glioblastoma patients? A retrospective analysis from an Italian registry (GLIOSTRY).. Journal of Clinical Oncology, 2016, 34, 2047-2047.	0.8	0
221	Natural History and Spontaneous Prognostic Factors. , 2017, , 307-322.		0
222	A phase II trial of temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: An AINO (Italian Association for Neuro-Oncology) study.. Journal of Clinical Oncology, 2017, 35, 2026-2026.	0.8	0
223	IDH-wild type low grade gliomas: An AINO (Italian Association of Neuro-Oncology) retrospective study.. Journal of Clinical Oncology, 2018, 36, 2050-2050.	0.8	0
224	Brain Metastases – Clinical Challenges and Recent Advances. European Neurological Review, 2019, 14, 20.	0.5	0
225	Epilepsy in CNS Metastases. , 2020, , 117-125.		0
226	Prevention Strategies for Brain Metastasis. , 2020, , 397-406.		0